GlassScriptPhysician profile
Jonathan C Bondroff
NPI 1306077797
$4,517.15
in general payments reported to CMS, 2019-2025
19 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $315 · 2021: $458 · 2022: $574 · 2023: $752 · 2024: $1,022 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Entertainment: $259 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Entertainment | $259.07 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,805.48 | 2019-2025 | Precision 1, Dailies Total1, Air Optix Color |
| Johnson & Johnson Vision Care, INC. | $1,195.05 | 2019-2025 | Acuvue |
| Optos, INC. | $259.07 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $226.18 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $146.81 | 2020-2021 | |
| Rxsight INC | $143.11 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $125.24 | 2023-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $96.42 | 2022-2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $90.16 | 2022-2024 | Cequa |
| Oyster Point Pharma, INC. | $88.16 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $73.57 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $59.30 | 2020-2023 | |
| Abb Con-Cise Optical Group LLC | $47.32 | 2019-2020 | |
| Glaukos Corporation | $43.01 | 2021 | |
| Dompe US, INC. | $33.24 | 2024 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.44 | 2021 | |
| Harrow Eye, LLC | $21.98 | 2024 | Vevye |
| Horizon Therapeutics Plc | $20.21 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bondroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.